NVDA
NVIDIA
-- 121.670 TSLA
Tesla
-- 249.980 PLTR
Palantir
-- 86.240 INTC
Intel
-- 24.050 QBTS
D-Wave Quantum
-- 10.150 
Update
$AEON Biopharma (AEON.US)$ AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
– Scheduled to hold a biosimilar initial advisory meeting with FDA in 3Q 2024 –
– 351(k) regulatory pathway offers potential to bring ABP-450 to the U.S. market under a single approval for all of BOTOX’s currently approved and future therapeutic indications –
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
– Scheduled to hold a biosimilar initial advisory meeting with FDA in 3Q 2024 –
– 351(k) regulatory pathway offers potential to bring ABP-450 to the U.S. market under a single approval for all of BOTOX’s currently approved and future therapeutic indications –
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment